Skip to main content
Premium Trial:

Request an Annual Quote

Amarantus Bio Moves Into Orphan Disease Theranostics, Raises $5.5M

NEW YORK (GenomeWeb) – Amarantus Bioscience Holdings is moving into diagnostics for orphan diseases and today announced it has completed a $5.5 million fundraising round.

The firm's diagnostics division holds the rights to MSPrecise, a proprietary next-generation sequencing assay for identifying patients with relapsing-remitting multiple sclerosis at first clinical presentation; an exclusive worldwide license to the Lymphocyte Proliferation test for Alzheimer's disease; and the intellectual property for NuroPro, a Parkinson's disease diagnostic test.

The firm issued $2.75 million in Series H convertible preferred stock and another $2.75 million in secured debt in a private placement to a single institutional investor. Both the Series H and the newly issued secured convertible debt are convertible into Amarantus common stock at $2.50 per share, subject to adjustment based on market conditions, the firm said in a statement.

Amarantus has also exchanged $2.9 million in secured debt previously issued to Dominion Capital for notes issued in connection with the secured debt financing agreement announced today.

Furthermore, the firm issued approximately 3.8 million warrants to the Series H holders and secured debt holders, exercisable for five years with a fixed strike price of $2.00.

At closing, Amarantus simultaneously repurchased all of the remaining 1,260 outstanding Series G convertible shares with a face value of $6.3 million and 212,087 common shares held by Discover Growth Fund, for a total of $4.75 million in cash. In April, Discover Growth Fund invested $5 million in Amarantus. The fund ho longer holds any securities of Amarantus and is precluded from trading in the firm for two years.

"While adverse market conditions have persisted in the entire biotechnology sector, we remain committed to our goal of achieving a national exchange listing, and believe this transaction is a significant step forward in positioning Amarantus toward reaching that important objective," Amarantus CFO Robert Farrell said in a statement.

Aegis Capital served as placement agent for the private placement.

The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.